Skip to main content
Erschienen in: PharmacoEconomics 2/2006

01.02.2006 | Original Research Article

Evaluation of Non-Medical Costs Associated with Visual Impairment in Four European Countries

France, Italy, Germany and the UK

verfasst von: Antoine Lafuma, Antoine Brézin, Stefania Lopatriello, Klaus Hieke, Julia Hutchinson, Viviane Mimaud, Dr Gilles Berdeaux

Erschienen in: PharmacoEconomics | Ausgabe 2/2006

Einloggen, um Zugang zu erhalten

Abstract

Introduction

Visual impairment is a severe disability that puts a heavy burden on individuals, families and society. In developed countries, the two major diseases leading to irreversible visual impairment are glaucoma and age-related macular degeneration. Their prevalence will increase dramatically with population aging. The economic consequences of visual impairment are considerable, but have rarely been documented, apart from some ‘top-down’ estimates based on national statistics. We estimated the non-medical costs related to visual impairment in four European countries: France, Italy, Germany and the UK.

Methods

Prevalence rates of visual impairment, defined according to local regulations, were taken from national registers and, for France, from two recent nationwide surveys conducted by the French Institute for National Statistics and Economic Studies (Institut National de la Statistique et des Etudes Economiques [INSEE]). Estimates of the number of non-registered persons were obtained from the literature and expert opinion. Estimates of non-medical costs included institutional care, non-medical devices, residential adaptations, burden on carer, paid home help, loss of income and social allowances related to visual impairment. Unit costs (year 2004) were extracted from national databases and manufacturers. Healthcare professionals were interviewed to estimate the duration of assistance required by visually impaired persons. These durations were used to evaluate the cost of paid assistance at home in the four countries.

Results

The numbers of visually impaired persons were 1.27 million in France, 0.73 million in Germany, 1.03 million in Italy and 1.11 million in the UK, including, respectively, 56%, 11%, 80% and 72% non-registered persons. The frequency of institutionalisation for visually impaired persons were, respectively, 7.8%, 9.6%, 10.9% and 10%. Total annual costs for visually impaired persons were estimated at €10 749 million in France, €9214 million in Germany, €12 069 million in Italy and €15 180 million in the UK. This translated into average annual costs per affected individual of €8434, €12 662, €11 701 and €13 674, respectively. The main cost components of visual impairment in the community were ‘loss of income’ (23–43% of community costs), ‘burden on carer’ (24–39%) and ‘paid assistance’ (13–29%).

Conclusion

Total non-medical costs associated with visual impairment are considerable. The present analysis demonstrates that the preponderant economic consequences of visual impairment lie beyond healthcare systems, and that visual impairment has a considerable negative impact on productivity. Considering the non-medical social dimensions of visual impairment related to the consequent incapacity and dependency should encourage payers to finance health innovations that aim to preserve vision.
Anhänge
Nur mit Berechtigung zugänglich
Fußnoten
1
Expert opinion was sought through an informal process, with at least two experts contacted for each country.
 
Literatur
1.
Zurück zum Zitat ResnikoffS, Pascolini D, Etya ’ale D, et al. Global data on visual impairment in the year 2002. Bull World Health Organ 2004; 82 (11): 844–851 ResnikoffS, Pascolini D, Etya ’ale D, et al. Global data on visual impairment in the year 2002. Bull World Health Organ 2004; 82 (11): 844–851
3.
Zurück zum Zitat OECD. Ageing in OECD countries: a critical policy challenge. Social Policy studies No. 20. Paris: OECD Publishing, 1996 OECD. Ageing in OECD countries: a critical policy challenge. Social Policy studies No. 20. Paris: OECD Publishing, 1996
4.
Zurück zum Zitat Robinson R, Deutcsh J, Jones HS, et al. Unrecognised and unregistered visual impairment. Br J Ophthalmol 1994; 78: 736–740PubMedCrossRef Robinson R, Deutcsh J, Jones HS, et al. Unrecognised and unregistered visual impairment. Br J Ophthalmol 1994; 78: 736–740PubMedCrossRef
5.
Zurück zum Zitat Wonnald R, Evans J. Registration of blind and partially sighted people. Br J Ophthalmol 1994; 78: 733–734CrossRef Wonnald R, Evans J. Registration of blind and partially sighted people. Br J Ophthalmol 1994; 78: 733–734CrossRef
6.
Zurück zum Zitat Bruce IW, McKennell AC, Walker EC. Blind and partially sighted adults in Britain: the RNIB survey. Vol. 1. London: HMSO, 1991 Bruce IW, McKennell AC, Walker EC. Blind and partially sighted adults in Britain: the RNIB survey. Vol. 1. London: HMSO, 1991
7.
Zurück zum Zitat Buch H, Vinding T, La Cour M, et al. The prevalence and causes of bilateral and unilateral blindness in an elderly urban Danish population: the Copenhagen City Eye Study. Acta Ophthalmol Scand 2001; 79 (5): 441–449PubMedCrossRef Buch H, Vinding T, La Cour M, et al. The prevalence and causes of bilateral and unilateral blindness in an elderly urban Danish population: the Copenhagen City Eye Study. Acta Ophthalmol Scand 2001; 79 (5): 441–449PubMedCrossRef
8.
Zurück zum Zitat Klaver CC, Wolfs RC, Vingerling JR, et al. Age-specific prevalence and causes of blindness and visual impairment in an older population: the Rotterdam Study. Arch Ophthalmol 1998; 116 (5): 653–658PubMed Klaver CC, Wolfs RC, Vingerling JR, et al. Age-specific prevalence and causes of blindness and visual impairment in an older population: the Rotterdam Study. Arch Ophthalmol 1998; 116 (5): 653–658PubMed
9.
Zurück zum Zitat Thylefors B, Negrel AD, Pararajasegaram R, et al. Available data on blindness (update 1994). Ophthal Epidemiol 1995; 2 (1), 5–39CrossRef Thylefors B, Negrel AD, Pararajasegaram R, et al. Available data on blindness (update 1994). Ophthal Epidemiol 1995; 2 (1), 5–39CrossRef
10.
Zurück zum Zitat Kocur I, Resnikoff S. Visual impairment and blindness in Europe and their prevention. Br J Ophthalmol 2002; 86: 716–722PubMedCrossRef Kocur I, Resnikoff S. Visual impairment and blindness in Europe and their prevention. Br J Ophthalmol 2002; 86: 716–722PubMedCrossRef
11.
Zurück zum Zitat Coffey M, Reidy A, Wormald R, et al. Prevalence of glaucoma in the west of Ireland. Br J Ophthalmol 1993; 77 (1): 17–21PubMedCrossRef Coffey M, Reidy A, Wormald R, et al. Prevalence of glaucoma in the west of Ireland. Br J Ophthalmol 1993; 77 (1): 17–21PubMedCrossRef
12.
Zurück zum Zitat Smith AF, Smith JG. The economic burden of global blindness: a price too high! Br J Ophthalmol 1996; 80 (4): 276–277PubMedCrossRef Smith AF, Smith JG. The economic burden of global blindness: a price too high! Br J Ophthalmol 1996; 80 (4): 276–277PubMedCrossRef
13.
Zurück zum Zitat Wright SE, Keefe JE, Thies LS. Direct costs of blindness in Australia. Clin Exp Ophthalmol 2000; 28 (3): 140–142CrossRef Wright SE, Keefe JE, Thies LS. Direct costs of blindness in Australia. Clin Exp Ophthalmol 2000; 28 (3): 140–142CrossRef
14.
Zurück zum Zitat Chiang YF, Bassi LJ, Javitt JC. Federal budgetary costs of blindness. Milbank Q 1992; 70 (2): 319–340PubMedCrossRef Chiang YF, Bassi LJ, Javitt JC. Federal budgetary costs of blindness. Milbank Q 1992; 70 (2): 319–340PubMedCrossRef
15.
16.
Zurück zum Zitat Frick KD, Foster A. The magnitude and cost of global blindness: an increasing problem that can be alleviated. Am J Ophthalmol 2003; 135 (4): 471–476PubMedCrossRef Frick KD, Foster A. The magnitude and cost of global blindness: an increasing problem that can be alleviated. Am J Ophthalmol 2003; 135 (4): 471–476PubMedCrossRef
18.
Zurück zum Zitat Brezin A, Lafuma A, Fagnani F, et al. Prevalence and burden of blindness, low vision and visual impairmentin the community: a nation-wide survey. Arch Ophthalmol 2005; 123 (8): 1117–1124PubMedCrossRef Brezin A, Lafuma A, Fagnani F, et al. Prevalence and burden of blindness, low vision and visual impairmentin the community: a nation-wide survey. Arch Ophthalmol 2005; 123 (8): 1117–1124PubMedCrossRef
19.
Zurück zum Zitat Brezin A, Lafuma A, Fagnani F, et al. Prevalence and burden of blindness and low vision for subjects living in institutions: a nation-wide survey. Health Qual Life Outcomes 2005; 3 (1): 27PubMedCrossRef Brezin A, Lafuma A, Fagnani F, et al. Prevalence and burden of blindness and low vision for subjects living in institutions: a nation-wide survey. Health Qual Life Outcomes 2005; 3 (1): 27PubMedCrossRef
20.
Zurück zum Zitat Brezin A, Lafuma A, Fagnani F, et al. Blindness, low vision and other handicaps as risk factors attached to institutional residence. Br J Ophthalmol 2004; 88 (10): 1330–1337PubMedCrossRef Brezin A, Lafuma A, Fagnani F, et al. Blindness, low vision and other handicaps as risk factors attached to institutional residence. Br J Ophthalmol 2004; 88 (10): 1330–1337PubMedCrossRef
21.
30.
Zurück zum Zitat Boissonnat V. Handicaps, incapacités, dépendance. Revue Française des Affaires Sociales 2003; No. 1–2 Boissonnat V. Handicaps, incapacités, dépendance. Revue Française des Affaires Sociales 2003; No. 1–2
31.
Zurück zum Zitat Engel H, Engels D. ISG Sozialforschung und Gesellschaftspolitik GmbH. Case management in various national elderly assistance systems. Publication series of the German Federal Ministry for Family Affairs, Senior Citizens, Women and Youth. Bd 18312. Cologne: Kohlhammer, 2000 Engel H, Engels D. ISG Sozialforschung und Gesellschaftspolitik GmbH. Case management in various national elderly assistance systems. Publication series of the German Federal Ministry for Family Affairs, Senior Citizens, Women and Youth. Bd 18312. Cologne: Kohlhammer, 2000
32.
Zurück zum Zitat Castiglioni M. Institutionalised old people: the experience of Italy. European Population Conference; 2001 Jun 7–9; Helsinki, Finland Castiglioni M. Institutionalised old people: the experience of Italy. European Population Conference; 2001 Jun 7–9; Helsinki, Finland
33.
Zurück zum Zitat Tinker A. Ageing in the United Kingdom: what does this mean for dentistry? Br Dental J 2003; 194 (7): 369–372CrossRef Tinker A. Ageing in the United Kingdom: what does this mean for dentistry? Br Dental J 2003; 194 (7): 369–372CrossRef
35.
Zurück zum Zitat Ministero della Sanità. Tariffe delle prestazioni di assistenza ospedaliera per acuti erogate in regime di ricovero ordinario e diurno ex d.m 30.06.1997 Ministero della Sanità. Tariffe delle prestazioni di assistenza ospedaliera per acuti erogate in regime di ricovero ordinario e diurno ex d.m 30.06.1997
36.
Zurück zum Zitat Netten A, Curtis L. The unit costs of health and social care, 2002. Kent: Personal Social Services Research Unit (PSSRU), 2002 Netten A, Curtis L. The unit costs of health and social care, 2002. Kent: Personal Social Services Research Unit (PSSRU), 2002
37.
Zurück zum Zitat OECD health data [database on CD ROM]. Paris: IRDES (Institut de Recherche et de Documentation en Economie de la Sante), 2004 OECD health data [database on CD ROM]. Paris: IRDES (Institut de Recherche et de Documentation en Economie de la Sante), 2004
38.
Zurück zum Zitat Guide Dogs for the Blind Association (GDBA). The costs of blindness: an analysis of the costs of visual impairment and blindness in the UK 2003 [online]. Available from URL: http://www.gdba.org.uk [Accessed 2004 Apr 14] Guide Dogs for the Blind Association (GDBA). The costs of blindness: an analysis of the costs of visual impairment and blindness in the UK 2003 [online]. Available from URL: http://​www.​gdba.​org.​uk [Accessed 2004 Apr 14]
39.
Zurück zum Zitat Berdeaux G, Lafuma A, Mimaud V. Estimation of nationwide costs of annual assistance attributable to visual impairment, from an activity of daily living questionnaire [abstract]. Value Health 2004; 7 (6): 748–749CrossRef Berdeaux G, Lafuma A, Mimaud V. Estimation of nationwide costs of annual assistance attributable to visual impairment, from an activity of daily living questionnaire [abstract]. Value Health 2004; 7 (6): 748–749CrossRef
43.
Zurück zum Zitat Caisse Nationale de l’ Assurance Maladie des Travailleurs Salariés. Indicateurs statistiques: résultats 2000–2001. Paris: Ed Caisse régionale d’Assurance Maladie de l’Ile de France, 2002 Caisse Nationale de l’ Assurance Maladie des Travailleurs Salariés. Indicateurs statistiques: résultats 2000–2001. Paris: Ed Caisse régionale d’Assurance Maladie de l’Ile de France, 2002
44.
Zurück zum Zitat Thylefors B, Negrel AD, Pararajasegaram R, et al. Available data on blindness (update 1994). Ophthalmic Epidemiol 1995; 2: 5–39PubMedCrossRef Thylefors B, Negrel AD, Pararajasegaram R, et al. Available data on blindness (update 1994). Ophthalmic Epidemiol 1995; 2: 5–39PubMedCrossRef
45.
Zurück zum Zitat Queginer P, Guillaumat L, Gattef C. Epidémiologie de la cécité dans les Bouches-du-Rhone. Approche méthodologique. Bull Soc Ophtalmol Fr 1988; 88: 21–22, 25, 26 Queginer P, Guillaumat L, Gattef C. Epidémiologie de la cécité dans les Bouches-du-Rhone. Approche méthodologique. Bull Soc Ophtalmol Fr 1988; 88: 21–22, 25, 26
46.
Zurück zum Zitat Coffey M, Reidy A, Wormald R, et al. Prevalence of glaucomain the west of Ireland. Br J Ophthalmol 1993; 77: 17–21PubMedCrossRef Coffey M, Reidy A, Wormald R, et al. Prevalence of glaucomain the west of Ireland. Br J Ophthalmol 1993; 77: 17–21PubMedCrossRef
47.
Zurück zum Zitat Klaver CC, Wolfs RC, Vingerling JR, et al. Age-specific prevalence and causes of blindness and visual impairment in an older population: the Rotterdam Study. Arch Ophthalmol 1998; 116: 653–658PubMed Klaver CC, Wolfs RC, Vingerling JR, et al. Age-specific prevalence and causes of blindness and visual impairment in an older population: the Rotterdam Study. Arch Ophthalmol 1998; 116: 653–658PubMed
48.
Zurück zum Zitat Causes and prevalence of visual impairment among adults in the United States: the Eye Diseases Prevalence Research Group. Arch Ophthalmol 2004; 122: 477–85 Causes and prevalence of visual impairment among adults in the United States: the Eye Diseases Prevalence Research Group. Arch Ophthalmol 2004; 122: 477–85
50.
Zurück zum Zitat Taylor H, Keefe J, Mitchell. The economic impact and cost of vision loss in Australia: Ed Eye research Australia. Melbourne, 2004 Aug [online]. Available from URL: http://www.cera.org.au [Accessed 2004 Mar 1] Taylor H, Keefe J, Mitchell. The economic impact and cost of vision loss in Australia: Ed Eye research Australia. Melbourne, 2004 Aug [online]. Available from URL: http://​www.​cera.​org.​au [Accessed 2004 Mar 1]
51.
Zurück zum Zitat Bonastre J, Le Pen C, Soubrane G, et al. The burden of agerelated macular degeneration: results of a cohort study in two French referral centres. Pharmacoeconomics 2003; 21 (3): 181–190PubMedCrossRef Bonastre J, Le Pen C, Soubrane G, et al. The burden of agerelated macular degeneration: results of a cohort study in two French referral centres. Pharmacoeconomics 2003; 21 (3): 181–190PubMedCrossRef
52.
Zurück zum Zitat Bonastre J, Le Pen C, Anderson P, et al. The epidemiology, economics and quality of life burden of age related macular degeneration in four European countries: France, Italy, Germany and the United Kingdom. Eur J Health Econ 2002; 3 (2): 94–102PubMedCrossRef Bonastre J, Le Pen C, Anderson P, et al. The epidemiology, economics and quality of life burden of age related macular degeneration in four European countries: France, Italy, Germany and the United Kingdom. Eur J Health Econ 2002; 3 (2): 94–102PubMedCrossRef
53.
Zurück zum Zitat Denis P, Lafuma A, Berdeaux G. Medical predictive factors of glaucoma treatment costs. J Glaucoma 2004; 13 (4): 283–290PubMedCrossRef Denis P, Lafuma A, Berdeaux G. Medical predictive factors of glaucoma treatment costs. J Glaucoma 2004; 13 (4): 283–290PubMedCrossRef
54.
Zurück zum Zitat Jonsson B, Krieglstein G. Primary open-angle glaucoma: differences in international treatment patterns and costs. Oxford: Ed Isis Medical Media, 1999 Jonsson B, Krieglstein G. Primary open-angle glaucoma: differences in international treatment patterns and costs. Oxford: Ed Isis Medical Media, 1999
55.
Zurück zum Zitat National Institute for Clinical Excellence. Guide to the methods of technology appraisal. London: NICE, 2004 [online]. Available from URL: http://www.nice.org.uk/ [Accessed 2004 Nov 23] National Institute for Clinical Excellence. Guide to the methods of technology appraisal. London: NICE, 2004 [online]. Available from URL: http://​www.​nice.​org.​uk/​ [Accessed 2004 Nov 23]
Metadaten
Titel
Evaluation of Non-Medical Costs Associated with Visual Impairment in Four European Countries
France, Italy, Germany and the UK
verfasst von
Antoine Lafuma
Antoine Brézin
Stefania Lopatriello
Klaus Hieke
Julia Hutchinson
Viviane Mimaud
Dr Gilles Berdeaux
Publikationsdatum
01.02.2006
Verlag
Springer International Publishing
Erschienen in
PharmacoEconomics / Ausgabe 2/2006
Print ISSN: 1170-7690
Elektronische ISSN: 1179-2027
DOI
https://doi.org/10.2165/00019053-200624020-00007

Weitere Artikel der Ausgabe 2/2006

PharmacoEconomics 2/2006 Zur Ausgabe